Pancreatic Cancer Clinical Trials in Houston, Texas

27 studies are recruiting for pancreatic cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

   This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson, Houston, Texas

   Run by

   ParVation Therapeutics, Inc.

   See if you can join NCT07756281 on ClinicalTrials.gov

2. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

3. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   86 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07252232 on ClinicalTrials.gov

4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

5. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

6. Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening

   To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07513116 on ClinicalTrials.gov

7. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

8. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   19 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

9. PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

   This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   PanTher Therapeutics

   See if you can join NCT06673017 on ClinicalTrials.gov

10. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    82 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

11. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Houston, Texas

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

12. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    23 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07277413 on ClinicalTrials.gov

13. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first tr…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Houston Methodist Office of Graduate - Houston Methodist Neal Cancer Center at Texas Medical Center, Houston, Texas

    Locations

    79 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT07409272 on ClinicalTrials.gov

14. CREO - Microwave Ablation Feasibility Study

    The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment w…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Hermann-Texas Medical Center, Houston, Texas

    Locations

    7 in total

    Run by

    Banner Health

    See if you can join NCT07817147 on ClinicalTrials.gov

15. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT MD Anderson, Houston, Texas

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

16. Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

    This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas

    Locations

    3 in total

    Run by

    Diakonos Oncology Corporation

    See if you can join NCT04157127 on ClinicalTrials.gov

17. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

    This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07066657 on ClinicalTrials.gov

18. A Study of DM002 in Patients With Advanced Solid Tumors

    The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas, MD Anderson Cancer Center, Houston, Texas

    Locations

    7 in total

    Run by

    Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

    See if you can join NCT06751329 on ClinicalTrials.gov

19. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

20. Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

    This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas Health Science Center at Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT07737171 on ClinicalTrials.gov

21. Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

    This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT02361320 on ClinicalTrials.gov

22. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

23. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center /ID# 270059, Houston, Texas

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

24. High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

    Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidit…

    Stage

    Not phased

    Ages

    19 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05053555 on ClinicalTrials.gov

25. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

    The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Md Anderson Cancer Center, Houston, Texas

    Locations

    18 in total

    Run by

    UMC Utrecht

    See if you can join NCT04075305 on ClinicalTrials.gov